Recursion Pharmaceuticals Inc.

# Signal Note: Casdin Capital Initiates RXRX Position Casdin's entry into Recursion signals confidence in the company's AI-driven drug discovery platform, which has demonstrated early clinical validation across multiple therapeutic areas. The $676K position size suggests moderate conviction rather than core holding, potentially reflecting either an initial probe or positioning ahead of upcoming clinical readouts or partnership announcements that could de-risk the platform's commercial viability.